Using large clinical BC transcriptomics datasets (The Cancer Genome Atlas [TCGA] and METABRIC), only patients with ESR1lo expression had higher levels of immune-related pathways like IFN, the inflammatory response, and APM signatures than did those with ESR1hi expression (Figure 1, C and D), suggesting a stronger immunogenic profile in ESR1lo patients. This evidence concerns the gene IFNA1 and breast cancer.